NEWS RELEASE: Velosity Announces Commercial Excellence Enhancements to Fuel Strategic Growth
Forest Lake, Minnesota, March 27, 2024 — Velosity, a state-of-the-art, custom contract manufacturer and solutions provider to the medical technology and pharmaceutical industries, today announced an exciting update to its commercial excellence framework aimed at outpacing market demands and fueling sustained growth. These organizational changes, effective Monday, March 18th, 2024, further position the company to capitalize on emerging opportunities in both sectors.
In response to the positive momentum and encouraging market shifts, Velosity is pleased to announce the appointment of Tom Caron as Vice President of Sales for strategic sectors. With decades of experience and a clear vision for success, Caron will spearhead the architecting of the structure and skill sets necessary to meet the anticipated growth in strategic markets. His expertise will be instrumental in ensuring Velosity’s competitiveness in securing high-value contracts within these sectors.
Joining Velosity in a pivotal leadership capacity is Greg Fischer, appointed as Vice President of Sales, Medical. Fischer brings extensive expertise in injection molding, mold making, and contract manufacturing, having previously served as Corporate Vice President of Sales and Marketing for National Mold and Vice President of Sales for iMark Molding. In his new role, Fischer will drive sales outreach efforts, with a particular emphasis on partnering with industry leaders in the MedTech, pharmaceutical, and life sciences segments within healthcare.
Lastly, elevating Velosity’s commercial capabilities further, Darren Bjork has been promoted to the role of Senior Vice President, Commercial. In this newly established position, Bjork will lead medical sales and marketing initiatives, focusing on high-growth clinical areas within the medical space. With a commitment to setting the vision and commercial strategy for above-market performance, Bjork’s leadership will play a pivotal role in positioning Velosity for long-term success.
Dave Hemink, Chief Executive Officer, expressed excitement about the company’s ability to invest in and further accelerate its commercial excellence and larger go-to-market strategy, crediting Tom Caron for building a “best-in-class” organization. He also extended congratulations to Darren Bjork on his well-deserved promotion and welcomed Greg Fischer to the Velosity team.
“These enhancements underscore our commitment to staying ahead of market trends and delivering exceptional value to our customers,” said Dave. “We are confident that the collective expertise of our leadership team, combined with our innovative solutions, will position Velosity for continued success in both the medical technology and pharmaceutical sectors.”
As Velosity embarks on this new chapter, the company invites its partners, stakeholders, and employees to join in celebrating the achievements of its dedicated team members and the opportunities that lie ahead.
About Velosity
Velosity is a leading provider of innovative solutions in the medical and defense industries. With a commitment to excellence and a focus on driving meaningful impact, Velosity delivers cutting-edge products and services that address the evolving needs of its customers worldwide. For more information, visit www.velosity.com.
The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
